Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
February 2016, Vol 7, No 1
February 2016, Vol 7, No 1
All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
February 2016, Vol 7, No 1
With the recent FDA approval of the first oral proteasome inhibitor ixazomib (Ninlaro), patients with relapsed or refractory multiple myeloma who have received previous treatment now have access to an all-oral regimen. The FDA-indicated triplet regimen of ixazomib, lenalidomide (Revlimid), and dexamethasone (Decadron) significantly improved progression-free survival (PFS) compared with the doublet of lenalidomide and dexamethasone, reported Philippe Moreau, MD, University of Nantes, France, at ASH 2015.
Read Article
Measuring Value in Healthcare to Improve Quality
By
Chase Doyle
Economics & Value
,
Value in Oncology
February 2016, Vol 7, No 1
Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination.
Read Article
Redesigning the Payment Model for Acute Leukemia: Benefits and Challenges of the Episode-of-Care Model
By
Chase Doyle
Value in Oncology
February 2016, Vol 7, No 1
Given the high cost of care for acute leukemia, innovative payment strategies that reward longitudinal care and create economic incentives for data-driven care delivery are needed, according to Joseph Alvarnas, MD, Director of Value-Based Analytics, and Associate Clinical Professor of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
Read Article
Value-Based Purchasing: Implications for Hematology
By
Chase Doyle
Value in Oncology
,
Value-Based Care
February 2016, Vol 7, No 1
Medicare has initiated several programs in the past decade to encourage value, but questions remain regarding their effectiveness. At ASH 2015, Andrew Ryan, PhD, MA, Associate Professor of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, addressed the implications of using financial incentives to drive care quality and reduce cost.
Read Article
The Hematologic Drug Pipeline: Exciting New Treatment Options Looming
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
February 2016, Vol 7, No 1
Many presentations at ASH 2015 focused on novel therapies currently in development for the treatment of patients with hematologic malignancies, including a second generation of new agents recently approved by the FDA for a variety of hematologic cancers.
Read Article
Clinical Pathways and the Oncology Medical Home: First Steps to Value-Based Patient Care
By
Chase Doyle
Clinical Pathways
,
Value in Oncology
February 2016, Vol 7, No 1
With $137 billion and growing spent on treatment in the US healthcare annually, cancer care delivery poses a significant challenge. At a special session at ASH 2015 on new payment models, Michael Kolodziej, MD, National Medical Director for Oncology Solutions at Aetna, discussed pathways and the medical home as transitional solutions to value in cancer care.
Read Article
Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
February 2016, Vol 7, No 1
The multikinase inhibitor midostaurin is the first targeted therapy to improve overall survival (OS) in patients with acute myeloid leukemia (AML) and the
FLT3
mutation.
Read Article
Multiple Myeloma Therapy in 2015: “An Extraordinary Moment in Oncology”
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
February 2016, Vol 7, No 1
The year 2015 saw an explosion of new drugs approved by the FDA and new indications for drugs already on the market for multiple myeloma. Overall, 4 new drugs from 2 new classes were approved in 2015, changing the standard of care for patients with this disease.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma